Liquidia Settles All Six United Therapeutics Suits, Will Pay Net $380.7 Million Through 2027
Liquidia keeps YUTREPIA on the market for PAH, drops its appeal and strips the PH-ILD use from the label.
Liquidia settled every pending lawsuit with United Therapeutics, agreeing to pay a net $380.7 million across 2026 and 2027, according to an 8-K dated October 13. In return, YUTREPIA stays on sale for pulmonary arterial hypertension (PAH), while Liquidia gives up its use for PH-ILD, a lung-disease-related form of the condition.
What the 8-K says
Liquidia will make a net payment of $175.0 million to United Therapeutics within 30 business days. That figure is net of money United Therapeutics pays Liquidia to settle the antitrust case over Treprostinil Injection.
Liquidia also owes $145.4 million in two equal installments of $72.7 million, due on or before January 31, 2027 and April 30, 2027.
Separately, Liquidia agreed to pay an aggregate of $60.3 million this month to the parties with interests in that antitrust case. The 8-K itemizes it: $21.75 million to Sandoz, $19.05 million to Henderson SPV and $19.45 million to PBM RG Holdings. PBM is a related party, controlled by board member and 5% holder Paul B. Manning and also owned by CEO Roger Jeffs, director Damian deGoa and General Counsel Russell Schundler. The board's disinterested members approved that deal.
The settlement covers six lawsuits, including patent cases and a North Carolina trade-secret and breach-of-contract fight. Liquidia agreed not to appeal the September 30 Delaware ruling that claims 1 and 14 of the '327 patent, covering PH-ILD treatment with inhaled treprostinil, are valid and infringed. It has filed to remove PH-ILD from YUTREPIA's label and stopped promoting that use. The press release says the deal is not an admission of liability.
What it changes
The mutual releases take effect only after Liquidia pays, the cases are dismissed with prejudice and the FDA approves the label change. The settlement does not reach indications other than PAH or new treprostinil products, and the filing warns United Therapeutics may assert patents against Liquidia's development programs.
To get a letter of credit tied to the deal, Liquidia needed consent from HealthCare Royalty Partners. It gave that by raising the minimum cash covenant from $15.0 million to $45.0 million.
The cushion: Liquidia reported $396.1 million in cash and equivalents at September 30, 2026, and preliminary, unaudited third-quarter YUTREPIA net product sales of $222.7 million. CFO Michael Kaseta said Liquidia expects to pay from YUTREPIA sales and cash on hand, and to rebuild cash and fund planned studies "without requiring additional financing." Liquidia also ended its Treprostinil Injection promotional agreement.
The stock closed at $26.81 in Monday's regular session, with the news coming after hours, according to Yahoo Finance.
What to watch
FDA action on the PH-ILD label removal gates the releases. Liquidia will give a broader update on sales, finances and pipeline on its third-quarter earnings call in November.
The first payment is due within 30 business days of October 13, and the last installment by April 30, 2027.
Sources
- 8-K Filing — Liquidia Corp (LQDA) — SEC EDGAR
- Exhibit tm2627557d1_ex99-1.htm — Liquidia Corp 8-K exhibit — SEC EDGAR
- Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360 — law360.com
- LQDA Explodes After Hours On Deal Ending Years Of Patent Fight, Keeping YUTREPIA On Market — Yahoo Finance